66th ASH Annual Meeting: Myeloid Malignancies Sessions

Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia - What Clinicians Want to Know

Friday Satellite Symposia

MDS 2024: Let’s Overcome the Challenges

Friday Satellite Symposia

Shifting to Higher Standards in MDS: Custom and Innovative Care to Improve Outcomes for Lower- and Higher-Risk Disease

Friday Satellite Symposia

Medical Crossfire®: Bridging Evidence to Practice in AML... Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Friday Satellite Symposia

Blood Buddies: Adult Clinical Malignant Hematology

Trainee Activities and Services

Blood Buddies: International Medical Graduates

Trainee Activities and Services

Epigenetic And Chromatin Mechanisms

Scientific Workshops

Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia - What Clinicians Want to Know

Friday Satellite Symposia

Poster Session I - Viewing

Events

A Little Less Conversation, a Little More Action: An Outcome Equity Roadmap for Children and AYAs With Leukemia and Lymphoma

Education Program

AML M&Ms: How to Integrate Mutations and MRD Data

Education Program

Ineffective Erythropoiesis: Insights Into Molecular Mechanisms and Disease Pathophysiology

Scientific Program

102. Iron Homeostasis and Biology: New Insights into Iron-related Proteins in Erythropoiesis and Inflammation

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Thrombotic Risk: The Genes We're Born with and Mutations We Acquire

Oral and Poster Abstracts

508. Bone Marrow Failure: Acquired: Biological Findings Associated with the Pathophysiology and Outcomes of Aplastic Anemia and PNH

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Cellular Mechanisms and Therapeutic Strategies

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Determinants of Venetoclax Resistance and Response

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: How Do We Start? Upfront Regimens with Commercially Available Therapies

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Multi-omic Applications for Disease Evolution and Response to Therapy

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Predicting and Treating Acute and Chronic GVHD

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Identifying Problems and Providing Solutions to Delivering Myeloid Malignancy Care

Oral and Poster Abstracts

Career Development Lunch

Trainee Activities and Services

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Know Thy(mus) Self, Know Thy Enemy: From Lymphocyte Genetic Variation to Disease

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Novel Therapeutic Strategies for Hematologic Disorders: From Mechanistic to Preclinical Studies

Oral and Poster Abstracts

Invivoscribe: Partnering with Pharma to Streamline Oncological Clinical Development

Company Showcases

Chasing Zebras: Navigating Rare Myeloid Neoplasms

Education Program

Ironing Out the Wrinkles: Managing Iron Overload in Different Clinical Scenarios

Education Program

503. Clonal Hematopoiesis, Aging, and Inflammation: Mechanisms of Hematopoietic Aging and Inflammation

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Disease Modeling and Molecular Mechanisms

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Novel Approaches to Targeting Epigenetics, Apoptosis and Immune Effectors in Myeloid Malignancies

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Menin Inhibitors in AML

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Impact of Molecularly-Targeted Agents in AML

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Measurable Residual Disease in AML in 2024 and Beyond

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Personalized and Molecular Approaches in Myeloproliferative Neoplasms: Risk Stratification and Therapeutic Implications

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: The Multimodal Future: AI Approaches to Drug Development, Classification and Outcomes

Oral and Poster Abstracts

Symposium on Quality: Treating Fairly - The Role of Quality Improvement in Combating Health Care Disparities

Special-Interest Sessions

The spatial organization of surface proteins of single cells in myelodysplastic syndrome for diagnostics and drug target discovery by Molecular Pixelation (MPX)

Company Showcases

Handling Bad News: How to Best Manage TP53 Myeloid Disease

Education Program

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Treatments and Outcomes in AML in Specific Age Groups, and in Blastic Plasmacytoid Dendritic Cell Neoplasms

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Functional Genomics in Prognosis and Novel Therapies

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Disease Mechanisms and Therapeutic Vulnerabilities in Molecular Genetic Subtypes of MDS

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Low Risk MDS

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Myeloid Biology and CAR-T Cells

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Learning from the Real World: Predictors of Outcomes in Understudied Lymphomas and Underrepresented Populations

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Patient Reported Outcomes and their Association with Clinical Outcomes in Patients with Myeloid Malignancies

Oral and Poster Abstracts

Poster Session I - Presentations (for in-person participants)

Events

201. Granulocytes, Monocytes, and Macrophages: Poster I

Oral and Poster Abstracts

301. Platelets and Megakaryocytes: Basic and Translational: Poster I

Oral and Poster Abstracts

401. Blood Transfusion: Poster I

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster I

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster I

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster I

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster I

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster I

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster I

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster I

Oral and Poster Abstracts

627. Aggressive Lymphomas: Pharmacologic Therapies: Poster I

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster I

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Poster I

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster I

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster I

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I

Oral and Poster Abstracts

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster I

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster I

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster I

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I

Oral and Poster Abstracts

801. Gene Therapies: Poster I

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster I

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster I

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Poster I

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Poster I

Oral and Poster Abstracts

909. Education, Communication, and Workforce: Poster I

Oral and Poster Abstracts

ASH Poster Walk on Deciphering the Hematopoietic Stem Cell Niche: From Normal Function to Malignancy Hosted by Blood Neoplasia (For In-person Participants)

ASH Poster Walks

Introducing a Therapeutic Option in Relapsed/Refractory AML/ALL

Industry Theaters

The Potential Impact of 24-Hour NGS Results on Myeloid and Lymphoid Malignancy Sample Characterization and Research

Industry Theaters

Poster Session II - Viewing

Events

Metabolic Deregulation in Hematopoietic Neoplasia: Tumor, The Environment, and Therapies.

Scientific Program

MPN Practice Pearls: Profiling, Pegylated IFN and Pregnancy

Education Program

201. Granulocytes, Monocytes, and Macrophages: Uncovering Pathways Impacting Inflammation, Myeloid Proliferation and Severe Congenital Neutropenia

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Clinical and Translational Insights from Patients and Models

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Frailty, Age, and Care Provisions-Impact on AML Outcomes

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Novel Molecules in Clinical Practice

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: JAK Inhibitors in MPDs, Novel Insights and Next-Gen Agents

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Enhancements in CAR-T Cell Signaling, Delivery & Manufacturing

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Conditioning and Donor Selection in Allogeneic Stem Cell Transplantation

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Social and Economic Disparities in Treatments, Outcomes and Financial Toxicity

Oral and Poster Abstracts

Addressing Critical Unmet Needs With Newly Diagnosed Ph+CML-CP

Product Theaters

A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS

Product Theaters

311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Big Data and Basic Science

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Long-term Outcomes Including in Bone Marrow Failure and Rare Diseases

Oral and Poster Abstracts

ASH-EHA Joint Symposium

Marquee Sessions

Race and Ancestry in Precision Medicine

Special-Interest Sessions

The Clone Wars: Myeloid Neoplasia Risk in Clonal Hematopoiesis

Spotlight Sessions

602. Myeloid Oncogenesis: Basic: Models and Mechanisms in AML Biology

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Deciphering the Mechanisms Underlying Prognosis

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing Treatment Paradigms in Myeloproliferative Neoplasms and Mastocytosis

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Treatment and Prognostication of MDS

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Finding the Ideal Donor and Graft: Going Beyond HLA

Oral and Poster Abstracts

905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Practice-Changing Outcomes Research for Patients with Thrombosis

Oral and Poster Abstracts

ASH Clinical Practice Guidelines on Amyloidosis

Special-Interest Sessions

Poster Session II - Presentations (for in-person participants)

Events

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster II

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster II

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster II

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster II

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II

Oral and Poster Abstracts

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Poster II

Oral and Poster Abstracts

614. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers, and Minimal Residual Disease in Diagnosis and Prognosis: Poster II

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster II

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster II

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster II

Oral and Poster Abstracts

623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster II

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Poster II

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Poster II

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster II

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Poster II

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster II

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster II

Oral and Poster Abstracts

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster II

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster II

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster II

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster II

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster II

Oral and Poster Abstracts

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Poster II

Oral and Poster Abstracts

ASH Poster Walk on Blood Immunology & Cellular Therapy: Advancing Innovations and Translational Insights Hosted by Blood Immunology & Cellular Therapy (For In-person Participants)

ASH Poster Walks

Poster Session III - Viewing

Events

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Resistance to Standard and Novel Therapies

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Stem Cell Biology in Myeloproliferative Syndromes

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Novel Approaches to Risk Stratification and Optimization for Transplant

Oral and Poster Abstracts

902. Health Services and Quality Improvement: Lymphoid Malignancies: For a Better Tomorrow - Improving Access to Blood Cancer Treatments and Trials

Oral and Poster Abstracts

903. Health Services and Quality Improvement: Myeloid Malignancies: Innovative Approaches to Improve Quality of Care, Affordability, and Outcomes

Oral and Poster Abstracts

ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies

Special-Interest Sessions

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

Product Theaters

506. Bone Marrow Microenvironment: The Bone Marrow Microenvironment in Disease

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Genetic Markers and Outcomes in AML

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Marker in Diagnosis and Prognosis: Refining Diagnostic Risk Assessment

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: New Insights into The Biology of Myeloproliferative Syndromes

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Novel Mechanisms of Aberrant Hematopoiesis and Immune Evasion in MDS

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: GVHD, GVL and Alloimmunity

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Enhancing NK Cell Therapeutics

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Exploring Biologic Mechanisms of Relapse and Survival

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Causes and Consequences

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Optimizing Regimens in Children/Young Adults and Around the World

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Alternative Laboratory Predictors of Outcome

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Advancing MPN Care: Innovative Therapies and Clinical Breakthroughs in Myelofibrosis

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Defining and Treating Chronic Myelomonocytic Leukemia

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-Term Follow up and Disease Recurrence: Novel Therapies to Prevent and Treat Disease Relapse

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Pioneering Tools for Tomorrow's Breakthroughs

Oral and Poster Abstracts

Poster Session III - Presentations (for in-person participants)

Events

201. Granulocytes, Monocytes, and Macrophages: Poster III

Oral and Poster Abstracts

203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster III

Oral and Poster Abstracts

332. Thrombosis and Anticoagulation: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Poster III

Oral and Poster Abstracts

503. Clonal Hematopoiesis, Aging, and Inflammation: Poster III

Oral and Poster Abstracts

506. Bone Marrow Microenvironment: Poster III

Oral and Poster Abstracts

509. Bone Marrow Failure and Cancer Predisposition Syndromes: Congenital: Poster III

Oral and Poster Abstracts

602. Myeloid Oncogenesis: Basic: Poster III

Oral and Poster Abstracts

603. Lymphoid Oncogenesis: Basic: Poster III

Oral and Poster Abstracts

604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Oral and Poster Abstracts

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III

Oral and Poster Abstracts

615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Oral and Poster Abstracts

617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III

Oral and Poster Abstracts

618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III

Oral and Poster Abstracts

619. Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment: Poster III

Oral and Poster Abstracts

631. Myeloproliferative Syndromes and Chronic Myeloid Leukemia: Basic and Translational: Poster III

Oral and Poster Abstracts

632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

636. Myelodysplastic Syndromes: Basic and Translational: Poster III

Oral and Poster Abstracts

637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

653. Multiple Myeloma: Clinical and Epidemiological: Poster III

Oral and Poster Abstracts

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Oral and Poster Abstracts

701. Experimental Transplantation: Basic and Translational: Poster III

Oral and Poster Abstracts

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Oral and Poster Abstracts

703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster III

Oral and Poster Abstracts

704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III

Oral and Poster Abstracts

711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III

Oral and Poster Abstracts

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III

Oral and Poster Abstracts

722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III

Oral and Poster Abstracts

723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III

Oral and Poster Abstracts

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III

Oral and Poster Abstracts

802. Chemical Biology and Experimental Therapeutics: Poster III

Oral and Poster Abstracts

803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: Poster III

Oral and Poster Abstracts

903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III

Oral and Poster Abstracts

906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III

Oral and Poster Abstracts

907. Outcomes Research: Plasma Cell Disorders: Poster III

Oral and Poster Abstracts

908. Outcomes Research: Myeloid Malignancies: Poster III

Oral and Poster Abstracts

2024 Presidential Symposium

Marquee Sessions

Myeloid Malignancies Sessions

Friday, December 6, 2024

7:00 AM-10:00 AM

11:00 AM-2:00 PM

1:30 PM-3:50 PM

ASH-a-Palooza

ASH-a-Palooza

2:03 PM-2:44 PM

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies

3:00 PM-6:00 PM

Saturday, December 7, 2024

9:00 AM-7:30 PM

9:30 AM-10:45 AM

9:30 AM-11:00 AM

11:15 AM-12:15 PM

12:00 PM-1:30 PM

1:30 PM-1:45 PM

2:00 PM-3:15 PM

2:00 PM-3:30 PM

3:30 PM-3:45 PM

4:00 PM-5:15 PM

4:00 PM-5:30 PM

5:30 PM-7:30 PM

Sunday, December 8, 2024

8:00 AM-9:00 AM

9:00 AM-8:00 PM

9:30 AM-10:45 AM

9:30 AM-11:00 AM

11:30 AM-12:30 PM

12:00 PM-1:30 PM

12:30 PM-1:30 PM

4:30 PM-5:45 PM

4:30 PM-6:00 PM

6:00 PM-8:00 PM

Monday, December 9, 2024

7:30 AM-8:30 AM

9:00 AM-8:00 PM

10:30 AM-12:00 PM

12:15 PM-1:15 PM

2:45 PM-4:15 PM

4:30 PM-6:00 PM

6:00 PM-8:00 PM

Tuesday, December 10, 2024

9:45 AM-11:15 AM